How long does riluzole prolong life?

How long does riluzole prolong life in ALS?

Riluzole is the first medicine shown to improve survival in amyotrophic lateral sclerosis (ALS). In the main controlled study that established its benefit, riluzole prolonged survival by about 2 to 3 months compared with placebo [1].

Does the survival benefit depend on how people are measured (months vs. survival rates)?

The reported “months” figure comes from overall survival comparisons in clinical trials, where participants are followed until death and compared across treatment groups. That means the exact time gain can look different depending on the population studied and the endpoint used (for example, median survival vs. average survival). In the pivotal evidence cited above, the benefit is consistently described as a few months rather than many months or years [1].

What does that mean for patients and caregivers?

A practical way to think about the evidence is that riluzole offers a modest survival extension—on the order of 2–3 months in the clinical-trial setting—without being curative. The degree of benefit can vary among individuals, but the trial-based estimate is in that range [1].

Source

[1] https://www.drugs.com/monograph/riluzole.html